Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: A report from the japanese pediatric leukemia/lymphoma study group

Daisuke Tomizawa, Akio Tawa, Tomoyuki Watanabe, Akiko Moriya Saito, Kazuko Kudo, Takashi Taga, Shotaro Iwamoto, Akira Shimada, Kiminori Terui, Hiroshi Moritake, Akitoshi Kinoshita, Hiroyuki Takahashi, Hideki Nakayama, Nobutaka Kiyokawa, Keiichi Isoyama, Shuki Mizutani, Junichi Hara, Keizo Horibe, Tatsutoshi Nakahata, Souichi Adachi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Infants (<1 year old) with acute myeloid leukemia (AML) are particularly vulnerable to intensive cytotoxic therapy. Indeed, the mortality rate was high among infants enrolled in the Japanese Pediatric Leukemia/ Lymphoma Study Group AML-05 study, which prompted us to temporarily suspend patient enrollment and amend the protocol. Forty-five infants with AML were enrolled. For patients aged < 2 years, drug doses were adjusted for body weight. Following the protocol amendments, doses for infants were reduced by a further 33 % in the initial induction course. Six infants died during the induction phase (including five early deaths), mainly due to pulmonary complications. The 3-year probability of overall survival (pOS) in all 45 infants [55.9 %, 95 % confidence interval (CI) 37.9-70.6 %] was significantly lower than that of patients aged 1 to <2 years (77.0 %, 95 % CI 62.7-86.3 %) and those aged ≥ 2 years (74.7 %, 95 % CI 69.2-79.4 %) (P = 0.037), mainly due to the higher nonrelapse mortality rate in infants. No early deaths occurred after the protocol amendments, and the 3-year pOS of the 17 infants enrolled thereafter was 76.4 % (95 % CI 48.8-90.4 %). In conclusion, appropriate dose reduction is essential to avoid early deaths when treating infants with AML.

Original languageEnglish
Pages (from-to)578-588
Number of pages11
JournalInternational journal of hematology
Volume98
Issue number5
DOIs
Publication statusPublished - Nov 1 2013

Keywords

  • Acute myeloid leukemia
  • Acute respiratory distress syndrome
  • Early death
  • Infants

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: A report from the japanese pediatric leukemia/lymphoma study group'. Together they form a unique fingerprint.

  • Cite this

    Tomizawa, D., Tawa, A., Watanabe, T., Saito, A. M., Kudo, K., Taga, T., Iwamoto, S., Shimada, A., Terui, K., Moritake, H., Kinoshita, A., Takahashi, H., Nakayama, H., Kiyokawa, N., Isoyama, K., Mizutani, S., Hara, J., Horibe, K., Nakahata, T., & Adachi, S. (2013). Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: A report from the japanese pediatric leukemia/lymphoma study group. International journal of hematology, 98(5), 578-588. https://doi.org/10.1007/s12185-013-1429-2